Free Trial
NASDAQ:KOD

Kodiak Sciences Q3 2023 Earnings Report

Kodiak Sciences logo
$2.84 +0.48 (+20.51%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$2.92 +0.08 (+2.85%)
As of 04/17/2025 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kodiak Sciences EPS Results

Actual EPS
-$0.95
Consensus EPS
-$1.41
Beat/Miss
Beat by +$0.46
One Year Ago EPS
N/A

Kodiak Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kodiak Sciences Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 14, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Kodiak Sciences' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Thursday, May 15, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Kodiak Sciences Earnings Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Kodiak Sciences reports Q4 EPS 84c, consensus (86c)
See More Kodiak Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kodiak Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kodiak Sciences and other key companies, straight to your email.

About Kodiak Sciences

Kodiak Sciences (NASDAQ:KOD), a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

View Kodiak Sciences Profile

More Earnings Resources from MarketBeat